Fundamentals Hub
▼ FY 2025 Summary Analysis
Annual report ending Dec 31, 2025Overview and Growth
Fiscal 2025 results for Aptose Biosciences Inc. combined $0.00 of revenue with net loss of $25.47M and an operating cash outflow of $21.99M. On a per-share basis, diluted EPS was -$10.41, which connects the reported earnings outcome with the company’s diluted share count. A diluted share base of 2.45M links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. The diluted share count was 250.1% higher than fiscal 2024, when diluted shares averaged 698.98K, adding context to the EPS comparison. At period end, total assets were $10.01M, framing the scale of the company’s operating and financing commitments.Profitability
After all below-operating-line items, the company recorded a net loss of $25.47M for the fiscal year. Income tax expense totaled $0.00, providing the reported tax component that separates pretax and after-tax earnings. The net loss equaled 254.4% of period-end assets, showing the deficit relative to the asset base. The net loss widened to $25.47M from $25.43M in fiscal 2024.Liquidity and Capital Structure
Total assets were $10.01M, supported by $37.18M of liabilities and -$27.17M of shareholder equity. The company reported negative equity of -$27.17M, a capital deficit that reduces its ability to absorb losses through book equity. Current assets were $6.45M against $9.31M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. The current ratio was 0.69x; current liabilities exceeded current assets, leaving a short-term liquidity deficit. The company held $935.00K in cash and equivalents, a narrower liquidity measure than total current assets. Cash and equivalents represented 10.0% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. Book equity represented -271.3% of total assets, quantifying the balance-sheet share supported by shareholder capital. Liabilities represented 371.3% of total assets, quantifying the liability-funded share of the company’s resource base. Measured against total assets, cash and equivalents represented 9.3%, a balance-sheet composition measure rather than a liquidity forecast. Total assets were 1.1% lower than fiscal 2024 assets of $10.13M, measuring the company’s own balance-sheet change. The reported cash balance changed 84.8% from $6.15M in fiscal 2024, ending lower year over year.Cash Flow and Earnings Quality
Operating activities used $21.99M of cash, resulting in an operating cash outflow for the year. Negative free cash flow was $21.99M, leaving a cash deficit after capital spending and reducing financial flexibility. Relative to total assets, the post-investment cash deficit measured 219.6%. Cash absorbed by operations decreased from $35.98M in fiscal 2024 to $21.99M.
Based on the annual report for the fiscal year ending Dec 31, 2025.
Analysis generated .